{"address1": "6550 South Millrock Drive", "address2": "Suite G50", "city": "Salt Lake City", "state": "UT", "zip": "84121", "country": "United States", "phone": "801 676 9695", "website": "https://clene.com", "industry": "Packaged Foods", "industryKey": "packaged-foods", "industryDisp": "Packaged Foods", "sector": "Consumer Defensive", "sectorKey": "consumer-defensive", "sectorDisp": "Consumer Defensive", "longBusinessSummary": "Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.", "fullTimeEmployees": 75, "companyOfficers": [{"maxAge": 1, "name": "Mr. Robert  Etherington MBA", "age": 57, "title": "CEO, President & Director", "yearBorn": 1967, "fiscalYear": 2023, "totalPay": 1059310, "exercisedValue": 0, "unexercisedValue": 160201}, {"maxAge": 1, "name": "Mr. Morgan R. Brown CPA, M.B.A.", "age": 56, "title": "Chief Financial Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 584885, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark G. Mortenson ESQ.", "age": 66, "title": "Chief Science Officer", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 729918, "exercisedValue": 0, "unexercisedValue": 100803}, {"maxAge": 1, "name": "Mr. Jerry  Miraglia J.D.", "title": "General Counsel & Corporate Secretary", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael T. Hotchkin", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mary Anne Mcneil", "title": "Head of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Benjamin M. Greenberg M.D., M.H.S.", "title": "Head of Medical", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.08, "open": 3.07, "dayLow": 2.57, "dayHigh": 3.1082, "regularMarketPreviousClose": 3.08, "regularMarketOpen": 3.07, "regularMarketDayLow": 2.57, "regularMarketDayHigh": 3.1082, "payoutRatio": 0.0, "beta": 0.263, "forwardPE": -0.7308782, "volume": 115034, "regularMarketVolume": 115034, "averageVolume": 54805, "averageVolume10days": 72800, "averageDailyVolume10Day": 72800, "bid": 0.0, "ask": 2.74, "bidSize": 0, "askSize": 5, "marketCap": 22244166, "fiftyTwoWeekLow": 2.57, "fiftyTwoWeekHigh": 9.2, "priceToSalesTrailing12Months": 65.04142, "fiftyDayAverage": 4.3484, "twoHundredDayAverage": 5.0779, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 30841066, "profitMargins": 0.0, "floatShares": 5849354, "sharesOutstanding": 8621770, "sharesShort": 86462, "sharesShortPriorMonth": 123805, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0104, "heldPercentInsiders": 0.36791, "heldPercentInstitutions": 0.18066, "shortRatio": 2.08, "shortPercentOfFloat": 0.0143, "impliedSharesOutstanding": 8621770, "bookValue": -1.095, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -39400000, "trailingEps": -5.67, "forwardEps": -3.53, "lastSplitFactor": "1:20", "lastSplitDate": 1720656000, "enterpriseToRevenue": 90.179, "enterpriseToEbitda": -0.981, "52WeekChange": -0.68536586, "SandP52WeekChange": 0.08089435, "quoteType": "EQUITY", "currentPrice": 2.58, "targetHighPrice": 84.0, "targetLowPrice": 20.0, "targetMeanPrice": 45.16667, "targetMedianPrice": 30.5, "recommendationMean": 1.5, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 12155000, "totalCashPerShare": 1.416, "ebitda": -31448000, "totalDebt": 20843000, "quickRatio": 1.219, "currentRatio": 1.57, "totalRevenue": 342000, "revenuePerShare": 0.049, "returnOnAssets": -0.51917, "returnOnEquity": -17.38363, "grossProfits": 272000, "freeCashflow": -8868125, "operatingCashflow": -21326000, "revenueGrowth": -0.465, "grossMargins": 0.79532, "ebitdaMargins": 0.0, "operatingMargins": -95.10989, "financialCurrency": "USD", "symbol": "CLNN", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Clene Inc.", "corporateActions": [], "regularMarketTime": 1743537600, "exchange": "NCM", "messageBoardId": "finmb_339429732", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "longName": "Clene Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1539869400000, "regularMarketChange": -0.5, "regularMarketDayRange": "2.57 - 3.1082", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 54805, "fiftyTwoWeekLowChange": 0.00999999, "fiftyTwoWeekLowChangePercent": 0.003891047, "fiftyTwoWeekRange": "2.57 - 9.2", "fiftyTwoWeekHighChange": -6.62, "fiftyTwoWeekHighChangePercent": -0.7195652, "fiftyTwoWeekChangePercent": -68.53658, "earningsTimestamp": 1742817601, "earningsTimestampStart": 1746534600, "earningsTimestampEnd": 1747053000, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -5.67, "epsForward": -3.53, "epsCurrentYear": -2.48667, "priceEpsCurrentYear": -1.0375321, "fiftyDayAverageChange": -1.7684002, "fiftyDayAverageChangePercent": -0.40667835, "twoHundredDayAverageChange": -2.4979, "twoHundredDayAverageChangePercent": -0.49191597, "priceToBook": -2.3561642, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Clene Nanomedicine Inc.", "nameChangeDate": "2025-04-01", "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "regularMarketChangePercent": -16.233767, "regularMarketPrice": 2.58, "marketState": "PRE", "displayName": "Clene", "trailingPegRatio": null}